N-LIfT PLATFORM PIPELINE
LIfT BioSciences patented N-LIfT cell therapy platform has the versatility to produce a range of different Immunomodulatory Alpha Neutrophils (IMANs) through a variety of production technologies. Our first generation technology uses Haemopoietic Stem Cells (HSCs) to produce IMANs with the source material and capacity to treat millions of patients. Our second generation production technology uses induced Pluripotent Stem Cells (iPSCs) with the aim of providing a limitless supply of IMANs even more cost-effectively. We also have second generation IMANs being engineered for further enhanced general and indication specific capabilities for specific solid tumours and other therapeutic areas.
Current Pipeline Stage in Development: